Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | DBH | P09172 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31451612 | 0.84 | CA2 (0.48) | CA2TP53CA1TSHRGAA | |
| SCHEMBL18037101 | 0.84 | CA2 (0.48) | CA2TP53CA1TSHRGAA | |
| SCHEMBL27566378 | 0.83 | FABP7 (0.42) | CA2TP53CA1TSHRGAA | |
| SCHEMBL3128978 | 0.80 | LIG1 (0.42) | CA2TP53CA1TSHRGAA | |
| SCHEMBL27572146 | 0.79 | CA2 (0.43) | CA2TP53CA1TSHRGAA | |
| SCHEMBL5072063 | 0.73 | MAOB (0.54) | CA2CA1TSHRLMNAALDH1A1 | |
| SCHEMBL5077616 | 0.71 | CA2 (0.50) | CA2TP53CA1TSHRGAA | |
| SCHEMBL3363979 | 0.71 | RAB9A (0.41) | CA2CA1LMNAHPGDKDM4E | |
| SCHEMBL28351226 | 0.71 | CA1 (0.62) | CA2TP53CA1TSHRLMNA | |
| SCHEMBL29773031 | 0.71 | CA2 (0.50) | CA2TP53CA1TSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119024654-A | Method for forming pattern | 三星SDI株式会社 | 2024-11-26 | — | — | CN | claimed |
| WO-2015059238-A1 | CORROSION INHIBITION OF REINFORCING STEEL EMBEDDED IN A CONCRETE STRUCTURE BY MEANS OF SURFACE APPLICATION OR BY ADDITION OF THE CORROSION-INHIBITING COMPOSITION TO THE FRESH REINFORCED CONCRETE | MAPEI S.P.A. (IT) | 2015-04-30 | — | — | WO | claimed |
| CN-119024654-A | Method for forming pattern | 三星SDI株式会社 | 2024-11-26 | — | — | CN | disclosed |
| US-9920083-B2 | Image recording paper medium and image recording method | FUJIFILM CORPORATION (JP) | 2018-03-20 | — | — | US | disclosed |
| US-20160250866-A1 | IMAGE RECORDING PAPER MEDIUM AND IMAGE RECORDING METHOD | FUJIFILM CORPORATION (JP) | 2016-09-01 | — | — | US | disclosed |
| WO-2015059238-A1 | CORROSION INHIBITION OF REINFORCING STEEL EMBEDDED IN A CONCRETE STRUCTURE BY MEANS OF SURFACE APPLICATION OR BY ADDITION OF THE CORROSION-INHIBITING COMPOSITION TO THE FRESH REINFORCED CONCRETE | MAPEI S.P.A. (IT) | 2015-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160250866-A1 | IMAGE RECORDING PAPER MEDIUM AND IMAGE RECORDING METHOD | PHOSPHO1, ITPR2, PPIP5K2 | CA2 33/4885TP53 3100/4885CA1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.